ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Mersana Therapeutics Inc

Mersana Therapeutics Inc (MRSN)

0.3534
-0.0265
(-6.98%)
0.37
0.0166
(4.70%)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.37
Bid
0.35
Ask
0.3718
Volume
1,446,273
0.351 Day's Range 0.3838
0.2589 52 Week Range 2.83
Market Cap
Previous Close
0.3799
Open
0.3838
Last Trade Time
Financial Volume
$ 527,617
VWAP
0.364812
Average Volume (3m)
2,815,984
Shares Outstanding
124,631,339
Dividend Yield
-
PE Ratio
-0.63
Earnings Per Share (EPS)
-0.56
Revenue
40.5M
Net Profit
-69.19M

About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Mersana Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRSN. The last closing price for Mersana Therapeutics was $0.38. Over the last year, Mersana Therapeutics shares have traded in a share price range of $ 0.2589 to $ 2.83.

Mersana Therapeutics currently has 124,631,339 shares outstanding. The market capitalization of Mersana Therapeutics is $47.35 million. Mersana Therapeutics has a price to earnings ratio (PE ratio) of -0.63.

MRSN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0131-3.419472722530.38310.4596830.3523908620.38557468CS
4-0.0134-3.495044340110.38340.4596830.330626134240.37177263CS
12-0.0721-16.30852748250.44210.4596830.258928159840.35879661CS
26-1.68-81.95121951222.052.120.258941217350.5790955CS
52-1.7-82.12560386472.072.830.258926017720.8958526CS
156-2.8-88.32807570983.179.620.258924868362.57360956CS
260-21.56-98.312813497521.9329.090.258918910414.69071323CS

MRSN - Frequently Asked Questions (FAQ)

What is the current Mersana Therapeutics share price?
The current share price of Mersana Therapeutics is $ 0.37
How many Mersana Therapeutics shares are in issue?
Mersana Therapeutics has 124,631,339 shares in issue
What is the market cap of Mersana Therapeutics?
The market capitalisation of Mersana Therapeutics is USD 47.35M
What is the 1 year trading range for Mersana Therapeutics share price?
Mersana Therapeutics has traded in the range of $ 0.2589 to $ 2.83 during the past year
What is the PE ratio of Mersana Therapeutics?
The price to earnings ratio of Mersana Therapeutics is -0.63
What is the cash to sales ratio of Mersana Therapeutics?
The cash to sales ratio of Mersana Therapeutics is 1.08
What is the reporting currency for Mersana Therapeutics?
Mersana Therapeutics reports financial results in USD
What is the latest annual turnover for Mersana Therapeutics?
The latest annual turnover of Mersana Therapeutics is USD 40.5M
What is the latest annual profit for Mersana Therapeutics?
The latest annual profit of Mersana Therapeutics is USD -69.19M
What is the registered address of Mersana Therapeutics?
The registered address for Mersana Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Mersana Therapeutics website address?
The website address for Mersana Therapeutics is www.mersana.com
Which industry sector does Mersana Therapeutics operate in?
Mersana Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 19.92
(190.04%)
57.35M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
EYENEyenovia Inc
$ 6.96
(134.34%)
29.94M
RBNERobin Energy Ltd
$ 10.60
(92.03%)
45.44M
RELIReliance Global Group Inc
$ 2.20
(86.44%)
19.29M
SDSTStardust Power Inc
$ 0.186
(-52.10%)
39.42M
SHOTWSafety Shot Inc
$ 0.0161
(-45.97%)
12.35k
RUNSunrun Inc
$ 5.78
(-40.04%)
120.05M
SEDGSolarEdge Technologies Inc
$ 15.94
(-33.53%)
33.14M
GOVXGeoVax Labs Inc
$ 0.8924
(-32.39%)
2.64M
PCSAProcessa Pharmaceuticals Inc
$ 0.2632
(16.93%)
575.5M
GNLNGreenlane Holdings Inc
$ 0.0104
(-16.13%)
392.94M
HCTIHealthcare Triangle Inc
$ 0.022
(-16.67%)
356.57M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.45M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.9373
(-7.75%)
143.55M

MRSN Discussion

View Posts
glenn1919 glenn1919 4 weeks ago
MRSN...................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
slef slef 1 month ago
Don't get stuck in the rs.
πŸ‘οΈ0
AKATITUS AKATITUS 2 months ago
😒 🤔
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
MRSN...........................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
AKATITUS AKATITUS 3 months ago
Guess
.45 is the bottom 🤔
πŸ‘οΈ0
glenn1919 glenn1919 3 months ago
MRSN..........................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
AKATITUS AKATITUS 4 months ago
Conference call tomorrow

https://finance.yahoo.com/news/mersana-therapeutics-provides-business-announces-120100840.html

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-ne...
πŸ‘οΈ0
AKATITUS AKATITUS 4 months ago
https://x.com/MersanaADC/status/1894402567268176148?t=QScofmUgyO7wUuukSylYWw&s=19
πŸ‘οΈ0
AKATITUS AKATITUS 4 months ago
Guess .50 is bottom
πŸ‘οΈ0
green maschine green maschine 4 months ago
I Anticipate a good week here
👍️ 1 🤑 1
glenn1919 glenn1919 4 months ago
MRSN................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
green maschine green maschine 4 months ago
🚀💰️
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
MRSN VOLUME TO DOLLA
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
MRSN GAPPA
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
MRSN.................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 months ago
MRSN MINI BIO GETTING VOLUME
πŸ‘οΈ0
glenn1919 glenn1919 5 months ago
MRSN.................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MRSN, under $2
πŸ‘οΈ0
glenn1919 glenn1919 8 months ago
MRSN.............................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 9 months ago
MRSN....................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
MRSN under $2
πŸ‘οΈ0
glenn1919 glenn1919 10 months ago
MRSN.............................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
MRSN under $2
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
MRSN under $2
πŸ‘οΈ0
Victor 11 Victor 11 1 year ago
WLAN will explode within a year
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
MRSN note the cup and handle
πŸ‘οΈ0
TimeFades TimeFades 2 years ago
Looking good still
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Picking up some
πŸ‘οΈ0
TimeFades TimeFades 2 years ago
Time for the push
πŸ‘οΈ0
Penny chatter Penny chatter 2 years ago
Pump it up
πŸ‘οΈ0
TimeFades TimeFades 2 years ago
Pre market pump incoming
πŸ‘οΈ0
Monksdream Monksdream 2 years ago
MRSN new 52 week low
πŸ‘οΈ0
nate2028 nate2028 2 years ago
*some at 0.8
πŸ‘οΈ0
nate2028 nate2028 2 years ago
Grabbed some below 0.8 let’s see
πŸ‘οΈ0
Butchmass Butchmass 2 years ago
Insider buying has happened yesterday. Form 4.
πŸ‘οΈ0
MiamiGent MiamiGent 2 years ago
Nice! Good luck and happy trading!
πŸ‘οΈ0
Butchmass Butchmass 2 years ago
Hey Miami, its already started to bounce.
πŸ‘οΈ0
MiamiGent MiamiGent 2 years ago
MRSN Down 58% on clinical hold. Due to severity of report, not sure of any bounceability.
πŸ‘οΈ0
bladerunner1717 bladerunner1717 2 years ago
MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner
πŸ‘οΈ0
bladerunner1717 bladerunner1717 2 years ago
MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner
πŸ‘οΈ0
MRDALE MRDALE 4 years ago
Hey there! I am looking for a stock that will double in a year. Is $MRSN that stock??? Looks like it could. TIA.
MrDale.
πŸ‘οΈ0
daleb2130 daleb2130 4 years ago
Just bought in. $20.27
πŸ‘οΈ0
dealerschool2006 dealerschool2006 4 years ago
Panic sale for MRSN today...results are considered positive...
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $MRSN Video Chart 09-14-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $MRSN Video Chart 05-27-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
MRSN 44%% up,$15.20 going
πŸ‘οΈ0
edwardport edwardport 5 years ago
AWESOME STOCK FOR SURE
πŸ‘οΈ0
edwardport edwardport 5 years ago
fantastic gain today of 21% for all of us expected
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
MRSN bio beast here...did not take a big hit in the crash!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
MRSN blowing up something is up here!!
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock